We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-16.77%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$140M
AUM Growth
-$33.4M
Cap. Flow
+$24.5K
Cap. Flow %
0.02%
Top 10 Hldgs %
90.94%
Holding
43
New
3
Increased
9
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$327K
2
AXDX
Accelerate Diagnostics
AXDX
+$282K
3
CELG
Celgene Corp
CELG
+$278K
4
PACB icon
Pacific Biosciences
PACB
+$266K
5
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$164K

Top Sells

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$508K
2
PTCT icon
PTC Therapeutics
PTCT
+$483K
3
GILD icon
Gilead Sciences
GILD
+$387K
4
CERS icon
Cerus
CERS
+$313K
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$221K

Sector Composition

Rank Sector Weight
1 Healthcare 91.79%
2 Energy 3.24%
3 Consumer Staples 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MACK
26
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$368K 0.26%
5,592
+1,779
+47% +$92.9K
ADXS
27
DELISTED
Advaxis Inc
ADXS
$321K 0.23%
2,373
– –
KURA icon
28
Kura Oncology
KURA
$958M
$320K 0.23%
79,114
-26,171
-25% -$124K
CELGZ
29
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$312K 0.22%
238,214
– –
TSRO
30
DELISTED
TESARO, Inc.
TSRO
$306K 0.22%
6,950
– –
GNCA
31
DELISTED
Genocea Biosciences, Inc.
GNCA
$302K 0.22%
+4,875
New +$155K
BIIB icon
32
Biogen
BIIB
$29.7B
$260K 0.19%
1,000
– –
PACB icon
33
Pacific Biosciences
PACB
$422M
$230K 0.16%
+27,000
New +$266K
TTHI
34
DELISTED
TRANSITION THERAPEUTICS INC (CANADA)
TTHI
$187K 0.13%
145,746
– –
RPTP
35
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$184K 0.13%
40,000
– –
ROKA
36
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$174K 0.12%
25,231
+10,000
+66% +$79.9K
ICPT
37
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$167K 0.12%
+1,300
New +$153K
XNCR icon
38
Xencor
XNCR
$1.41B
$165K 0.12%
12,300
– –
CHRS icon
39
Coherus Oncology
CHRS
$219M
$159K 0.11%
7,500
– –
CERS icon
40
Cerus
CERS
$639M
$157K 0.11%
26,500
-56,500
-68% -$313K
AGIO icon
41
Agios Pharmaceuticals
AGIO
$2.38B
– –
-3,400
Closed -$221K
GILD icon
42
Gilead Sciences
GILD
$166B
– –
-3,820
Closed -$387K
PTCT icon
43
PTC Therapeutics
PTCT
$6.51B
– –
-14,900
Closed -$483K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2016 Portfolio in Review

As of Q1 2016, Birchview Capital held 43 positions worth $140M, down 19% from $174M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q1 2016 filing shows 3 new, 9 increased, 4 reduced and 3 closed positions. Its largest new stake was Pacific Biosciences: 27,000 shares worth $230K. The largest sale was MEDIVATION, INC., an estimated $508K.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 94% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2016 buy was Pacific Biosciences: 27,000 shares worth $230K.
  • Birchview Capital added most to Collegium Pharmaceutical in Q1 2016, an estimated $327K increase.
  • Birchview Capital's biggest Q1 2016 reduction was MEDIVATION, INC., cutting an estimated $508K.
  • Birchview Capital fully exited PTC Therapeutics in Q1 2016, selling an estimated $483K.
  • Birchview Capital's ten largest holdings make up 91% of its $140M portfolio in Q1 2016.
  • Birchview Capital opened 3 new positions and closed 3 in Q1 2016.
  • Birchview Capital's portfolio value fell 19% quarter-over-quarter to $140M.

Based on Birchview Capital's 13F filing for Q1 2016, filed 28 Apr 2016.